Compare CarMax, Inc (KMX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Moderna, Inc. — how do they compare? CarMax, Inc trades at $57.79 (market cap $7.93B), while Moderna, Inc. trades at $59.29 (market cap $23.60B). The key difference: Moderna, Inc. is far larger — about 3× CarMax, Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| KMX | MRNA | |
|---|---|---|
Market Cap | $7.93B | $23.60B |
Sector | Consumer Cyclical | Health |
52-Week High | $63.53 | $81.80 |
52-Week Low | $30.88 | $22.36 |
Enterprise Value | $26.44B | $19.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $55.89, down 2.51% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported mixed earnings, with a Q2 2025 miss but subsequent beats in Q3 2025 and Q1 2026. Revenue has trended down from $31.9B in 2022 to $26.35B in 2025, though net income margin improved slightly to 1.89%. Recent news highlights a strategic turnaround under new CEO Keith Barr, with insider buying and positive analyst updates despite an ongoing legal investigation.
The outlook for KMX hinges on successful execution of its four-pillar strategy to boost volume and efficiency, offering potential upside if targets are met. However, high debt levels, margin pressure, and legal scrutiny pose significant risks. Analyst consensus is cautious with a hold-heavy rating and a price target of $48.91 below the current price, indicating skepticism about near-term growth.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
